Stem Cell Transplant in India by Dr.BS Rajput Dr.BS Rajput Sr.Consultant Orthopedic Stem Cell Transplant Surgeon mob-+91 9820850187,9811763787 drrajput09820850187@gmail.com http://www.drrajput.inFrom:ZandZMediaViews:4 0ratingsTime:11:49More inScience Technology Read more here: Stem Cell Transplant in India by Dr.BS Rajput - Video … Continue reading →

Stem Cell's explained part 1 on The Susana Kennedy Show on 2oceansvibe My ever increasing curiosity with the possibilities of Stem Cell therapy recently led me to meeting up with Dr. Duncan Carmichael from The Anti-Aging Clinic in Cape town, we chatted about what stem cell's are, what some of the possibilities are and more, this is part one of a series of interviews I will be releasing over the next few weeks, demystifying the myths and revealing the incredible possibilities that are actually already available to you all right now. Enjoy!From:Susana KennedyViews:2 0ratingsTime:08:32More inScience Technology Read the original: Stem Cell's explained part 1 on The Susana Kennedy Show on 2oceansvibe - Video … Continue reading →

WATERTOWN, Mass.--(BUSINESS WIRE)-- Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat debilitating diseases, announced today the appointment of Mark Iwicki as the companys President and Chief Executive Officer and a member of the board of directors. Mr. Iwicki brings to Blend Therapeutics more than 23 years of experience as a pharmaceutical industry leader managing all stages of drug development and in multiple therapeutic areas, including his most recent positions as Chief Executive Officer of Sunovion Pharmaceuticals and Chief Commercial Officer of Sepracor. "With oncology as our initial focus and multiple first-in-class anti-cancer drugs in our pipeline, we are extremely pleased that Mark, who has a long track record of success in the biopharma industry, has become Blends CEO, said Omid Farokhzad, MD, founder and director of Blend Therapeutics and Associate Professor at Harvard Medical School. "Mark has extensive experience managing high-performance teams and has been instrumental in the success of drugs including Prilosec, Diovan, Zelnorm, and Lunesta. The combination of his business leadership, strategic vision and drug development expertise will be a great asset as Blend capitalizes on the vast potential of its platform to develop entirely new classes of drugs to treat patients with … Continue reading →

WATERTOWN, Mass.--(BUSINESS WIRE)-- Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat debilitating diseases, announced today that it has secured a $16 million Series B financing. Blend is pioneering an integrative model for discovering novel molecular entities with new mechanisms of action purposely designed for Blends proprietary nanoparticles. By synergistically developing both the molecule and the nanoparticle together, Blend can make medicines more targeted, more effective and more tolerable. NanoDimension led the Series B round with participation from other existing investors, Flagship Ventures and New Enterprise Associates. Proceeds from the financing will be used to expand Blends product and business development teams and to advance the companys lead programs through studies to enable filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA). The funding will enable Blend to pursue its initial focus in oncology as the company continues research and development of new classes of platinum drugs. The company will expand the development of its proprietary molecules for oncology, which include a portfolio of mono-functional platinums that have an entirely different mode of DNA platination and unprecedented biological differentiation compared to that of existing platinum drugs. Blends platinum drug … Continue reading →

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed an agreement with Octane Biotech of Kingston, Ontario, to jointly develop a proprietary bioreactor for production of its NurOwn stem cell therapy candidate. The customized bioreactor will enable BrainStorm to optimize its NurOwn production process, significantly increasing its production capabilities by using a single clean room for multiple patients, reducing costs and time. The project is supported by a grant awarded by the Canada-Israel Industrial Research and Development Foundation (CIIRDF). Under the terms of the agreement, the companies will develop a commercially viable, safe, reliable, and cost-effective bioreactor for scale-up of BrainStorms NurOwn stem cell therapy, using Octanes Automated Cell & Tissue Engineering System (ACTES) technology. The CIIRDF funding award was approved for a period of three years. Octane is the ideal partner for us, since they have a particular expertise in developing automated production processes for mesenchymal cell therapy technologies, commented Dr. Adrian Harel, BrainStorms CEO. We are anxious to move ahead with this project, in order to be in a position to provide NurOwn as quickly as possible, and to … Continue reading →